Once rejected, Kala's dry eye drug now gains entry to a field where Novartis is grooming its own blockbuster
When the FDA slapped a rejection on Kala Pharma’s dry eye drug last August, the biotech’s execs promised investors that a third Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
